Professional FAQ
Questions UK clinicians ask about ChondroFiller.
Short answers with their sources, for clinicians weighing up ChondroFiller® liquid. Each answer links to the page that covers it in full.

Common questions
What clinics ask before a first case.
What is ChondroFiller?
A cell-free, two-component type I collagen matrix of animal origin (rat tail tendon), as described in the published literature, supplied as a collagen solution and a neutralising solution that are mixed through an adapter at the point of use and form a stable gel in the prepared defect within minutes.1,2
What are the indications?
Grade III to IV cartilage damage in the knee, hip, shoulder, ankle or the small joints of the hand, for defects up to 3 cm², per the manufacturer’s product page.3
What are the contraindications?
What does the published evidence show?
Published evidence is mostly small, single-arm or retrospective cohorts and case reports. Knee studies include a 23-patient multicentre trial and a 17-patient prospective study to 12 months. Hip studies include a 26-patient cohort followed 12 to 60 months and a 23-patient retrospective series followed for a mean of 29 months. An ankle series of 21 patients was followed for a mean of 37 months. No shoulder outcome data were found.6,7,8,9,10
What is the safety profile?
The manufacturer states: 'In rare cases, hypersensitivity reactions to collagen such as allergic or inflammatory reactions can occur. There are no known complications caused by the implant of ChondroFiller® liquid.' No adverse events were reported in a multicentre trial of 23 randomised patients, 13 of whom received ChondroFiller.5,6
How is ChondroFiller handled and stored?
How do we order ChondroFiller and arrange training?
Actomed provides product training, first-case support and an IFU walkthrough for new clinics. Contact Actomed to discuss formats and lead time.
How do we report an adverse event or product issue?
Report suspected incidents or product quality issues to Actomed, the UK Responsible Person, who handles reporting to the manufacturer and, where required, to the MHRA.
Is ChondroFiller MHRA approved?
ChondroFiller is listed on the MHRA register of medical devices. Registration is not approval. It is CE marked by the manufacturer and accepted on the Great Britain market under the current transitional arrangements for CE-marked devices.
In more depth
Where each answer is covered in full.
The professional section, page by page.
References
- 1.Perez-Carro L, Mendoza Alejo PR, Gutierrez Castanedo G, Menendez Solana G, Fernandez Divar JA, Galindo Rubin P, Alfonso Fernandez A. Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. Arthroscopy Techniques, 10(7):e1669-e1675, 2021. View DOI
- 2.Meidrix Biomedicals GmbH. ChondroFiller® liquid overview brochure. Manufacturer publication, 2024. View source
- 3.Meidrix Biomedicals GmbH. ChondroFiller® liquid product page. Meidrix Biomedicals GmbH, 2026. View source
- 4.Meidrix Biomedicals GmbH. ChondroFiller® liquid instructions for use. Meidrix Biomedicals GmbH, 2026. View source
- 5.Meidrix Biomedicals GmbH. ChondroFiller® liquid patient education leaflet. Manufacturer publication, 2022. View source
- 6.Schneider U. Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid (cell free 2-component collagen gel) with microfracturing of patients with focal cartilage defects of the knee joint. Video Journal of Orthopedics Surgery, 1:1-8, 2016. View DOI
- 7.Simeonov E. Implantation of ChondroFiller Liquid as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. Journal of IMAB, 30(4):5936-5941, 2024. View DOI
- 8.Mazek J, Gnatowski M, Salas AP, O’Donnell JM, Domżalski M, Radzimowski J. Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. Journal of Hip Preservation Surgery, 8(1):22, 2021. View DOI
- 9.De Lucas Villarrubia JC, Méndez Alonso MÁ, Sanz Pérez MI, Trell Lesmes F, Panadero Tapia A. Acellular Matrix-Induced Chondrogenesis Technique Improves the Results of Chondral Lesions Associated with Femoroacetabular Impingement. Arthroscopy, 2021. View DOI
- 10.Gatti SD, Vermorel PH, Vega J, Batista J, Guelfi M. Clinical and functional outcomes of arthroscopic autologous collagen-induced chondrogenesis (ACIC) for osteochondral lesions of the talus: A retrospective case series. Journal of Experimental Orthopaedics, 13(1):e70642, 2026. View DOI
Not answered here? Ask Actomed.
Product, evidence, IFU, training or ordering questions go to the enquiry form. Actomed replies to the work email address given.